Tangram Therapeutics has submitted a Clinical Trial Application to the UK MHRA to begin a Phase 1/2 study of TGM-312, a GalNAc-conjugated siRNA designed to silence a novel hepatocyte target in metabolic dysfunction–associated steatohepatitis. The first-in-human program will run in the United Kingdom with healthy volunteers and MASH patients, assessing safety, PK/PD, and including liver biopsies alongside exploratory imaging and biomarker endpoints. Pending clearance, dosing is planned to start in early 2026, with initial readouts expected in the second half of 2026. The candidate is pitched for potential quarterly subcutaneous dosing.
The filing moves Tangram’s GalOmic RNAi platform into the clinic and places another modality into an increasingly crowded MASH pipeline. After the first approval in the category and continued momentum for GLP‑1–based regimens reshaping metabolic disease, an RNAi approach will need to demonstrate either clear differentiation on tolerability and adherence or meaningful additive efficacy to weight-loss–driven improvements. Tangram has not disclosed the target, framing this as a novel hepatocyte gene. Preclinical claims include reductions in NAS and fibrosis progression in a mouse model, as monotherapy and in combination, but clinical value will turn on human PD and histology.
Choosing the UK for first-in-human is a pragmatic operational call. MHRA continues to offer predictable CTA timelines, and the UK has established infrastructure for early-phase hepatic studies, including biopsy logistics and centralized digital pathology. The trial’s design—combining SAD/MAD cohorts in healthy volunteers with an early patient expansion—aims to compress proof-of-mechanism by linking target engagement to histologic and noninvasive signals. Inclusion of imaging and circulating biomarkers acknowledges the regulatory shift toward noninvasive endpoints while still generating biopsy evidence that remains influential for portfolio gating and potential later-stage design.
For sites, this is another biopsy-capable MASH study entering an already competitive recruitment environment. Centers with MRI-PDFF, MRE, cT1, and fibrosis biomarker capabilities may see incremental demand, while operational burden will hinge on the frequency of biopsies and laboratory monitoring typical for RNAi programs. CROs with hepatology networks and biopsy standardization will be critical to timeline fidelity. Vendors focused on assay sensitivity for PD readouts—especially if the target has a measurable secreted or metabolic signature—could benefit from early adoption in protocol amendments as data emerge.
For sponsors and competitors, an RNAi entrant underscores the ongoing diversification of MASH mechanisms beyond thyroid hormone receptor agonism and incretin pathways. Quarterly dosing, if achieved without safety trade-offs, would be commercially relevant in maintenance settings and could be tested as an add-on to GLP‑1s or THR‑β agonists, provided drug–drug interactions and overlapping safety signals are manageable. Regulators will scrutinize target specificity, off-target risk, and durability in a largely asymptomatic population, alongside CMC robustness for GalNAc-siRNA manufacture and conjugation consistency.
The near-term watch list is straightforward: MHRA’s review timeline and any protocol details on cohort sizes and biomarker strategy; disclosure of the molecular target and degree of knockdown in humans; the balance of biopsy and noninvasive endpoints; and whether Tangram opens a parallel US IND to broaden site access. Initial 2H26 data will likely be safety, PK, and early PD, with any biopsy readouts serving as directional signals rather than registrational surrogates. The strategic question is whether RNAi can carve out a role in MASH that complements metabolic therapies, and whether Tangram can move quickly enough—on data, combinations, and geographies—to secure relevance as standards of care evolve.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
